Objective: To evaluate the efficacy of tamsulosin on BPH patients with acute urinary retention on trial without catheter (TWOC). Materials & method: This study was a post test only-placebo group design comparing residual urine in BPH patients with acute urinary retention on TWOC between groups administered with tamsulosin and placebo. The efficacy of both groups with tamsulosin and placebo on the 3rd and 14th day was analyzed using Chi Square test while the efficacy of administration of tamsulosin and placebo on the 3rd and 14th day was analized using Mc Nemar test. Results: This study showed that there was still urinary retention in 7 patients (58,3%) and 4 patients (44,4%) shared recovery within 3 days of tamsulosin administration, while 5 patients (41,7%) still had urinary retention compared to 5 patients (55,6%) who showed recovery in the placebo group. The difference was insignificant with p=0,670. Patients who dropped out from TWOC on the 3rd day and given tamsulosin until the 14th day showed urinary retention in 4 patients (44,4%) and recovery in 3 patients (100%) while all samples who were given placebo showed urinary retention 5 patients (55,6%). The difference was insignificant with p=0,205. Follow up for 3 days in Tamsulosin groups which have urine retention in this study, 3 patients became free for urine retention and the other 4 patients still had urine retention. But in this study, no difference in efficacy with p=1,025. In placebo groups with urinary retention before the 3rd day of administration still showed urinary retention after the 14th day. Conclusion: There was no statistical differences on the success of TWOC, between groups administered with 0,2 mg of tamsulosin and placebo group, neither on the 3rd day nor on the 14th day. There was reduction of recatheterization because of failure of TWOC with patients who were given tamsulosin for 14 days.
BPH, tamsulosin, TWOC, urinary retention
Shah T, Palit V, Biyani S, Elamsry Y, Puri R, Flannigan GM. Randomised, plasebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. European Urology 2002; 42: 329-32.
Tuncel A, Uzun B, Eruyar T, Karabulut E, Seckin S, Atan A. Do prostatic infraction, prostatic inflammation, and prostate morphology play a role in acute urinary retention? European Urology 2005; 48: 277-84.
Gratzke C, Reich O, Staehler M, Seitz M, Schlenker B, Stief CG. Risk assessment and medical management of acute urinary retention in patients with benign prostatic hyperplasia. EAU-EBU Update Series 2006; 4: 109-16.
McNeill SA, Hargreave TB. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. Journal of Urology 2004; 171: 2316-20.
Lucas M, Stephenson T. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU 2005; 95: 354-7.
Lepor H, Lowe FC. Evaluation and nonsurgical management of benign prostatic hyperplasia. In Walsh PC, Retik AB, et al. Campbell’s Urology, 8th ed. 2002. p. 1337-78.
Presti JC. Neoplasma of the prostate gland. In Tanagho EA, Mc Anich JW. Smith’s General Urology, 15th ed. 2000. p. 399-417.
Rosette JL, Alivizatos G. Guidelines on benign prostatic hyperplasia. In Guidelines of European Association of Urology, 2008 ed. 2008.
Jones DA. Benign prostatic hypertrophy and lower urinary tract dysfunction. In Comprehensive Urology; 2001. p. 451-643.